- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Warburg Pincus acquires B&L
Warburg Pincus has completed its acquisition of Bausch & Lomb (B&L) for a total purchase price of approximately $4.5 billion, including nearly $830 million of debt.
Rochester, NY-Warburg Pincus has completed its acquisition of Bausch & Lomb (B&L) for a total purchase price of approximately $4.5 billion, including nearly $830 million of debt.
"With a strong and supportive partner in Warburg Pincus, we are well positioned to create new opportunities for Bausch & Lomb and advance our leadership in the eye health industry," said Ronald L. Zarrella, chairman and chief executive officer of B&L.
Elizabeth H. Weatherman, a Warburg Pincus managing director, said, "We're delighted to be partners with B&L. We look forward to helping the company build upon its rich heritage and premier brand in ophthalmology."
